Publications by authors named "Victoria Vilalta Del Olmo"
Background: The ACURATE neo2 is a contemporary transcatheter aortic valve implantation (TAVI) system approved for the treatment of severe aortic stenosis in Europe. The ACURATE neo2 has not been evaluated in bicuspid aortic valve (BAV) stenosis.
Aims: We sought to evaluate the safety and efficacy of ACURATE neo2 in patients with BAV stenosis.
Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI).
Basic Res Cardiol
January 2021
Remote ischemic conditioning (RIC) and the GLP-1 analog exenatide activate different cardioprotective pathways and may have additive effects on infarct size (IS). Here, we aimed to assess the efficacy of RIC as compared with sham procedure, and of exenatide, as compared with placebo, and the interaction between both, to reduce IS in humans. We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the safety and effectiveness of ultrathin strut polymer-free sirolimus-eluting stents (PF-SES) in a diverse patient population undergoing percutaneous coronary interventions (PCI).
- A total of 7243 patients were included, showing a low target lesion revascularization (TLR) rate of 2.2% and a stent thrombosis rate of 0.7% over 9-12 months of follow-up.
- The results indicate that PF-SES are safe and effective, with particularly high procedural success rates in challenging cases like in-stent restenosis and isolated left main coronary artery disease.
Article Synopsis
- The study aimed to evaluate regional and ethnic differences in patients treated with polymer-free sirolimus-eluting stents (PF-SES) across Asia and Europe.
- It combined data from two observational studies, analyzing 7243 patients and focusing on target lesion revascularization (TLR) rates and major cardiovascular events (MACE) over 9-12 months.
- Results showed low TLR (2.2%) and MACE (4.4%) rates across regions, with notably longer dual antiplatelet therapy (DAPT) in Asia compared to Europe, indicating that longer DAPT may lead to even lower clinical event rates.